MedTrace Logo

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

NCT06508346 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2024-12-02

No results posted yet for this study

Summary

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset refractory ANCA-Associated Vasculitis.

Conditions

  • ANCA Associated Vasculitis
  • CAR-T Cell Therapy

Interventions

BIOLOGICAL

anti-CD19-CAR-T cells

Intravenous injection

Sponsors & Collaborators

  • Children's Hospital of Chongqing Medical University

    collaborator OTHER

  • The Children's Hospital of Zhejiang University School of Medicine

    lead OTHER

Principal Investigators

  • Jianhua Mao, PhD · Children's Hospital, Zhejiang University School of Medicine

  • Mo Wang, PhD · Children's Hospital of Chongqing Medical University

Eligibility

Min Age
5 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2026-07-31
Completion
2027-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06508346 on ClinicalTrials.gov